people on another board didn't want to hear this, but the hurricane plays are gonna take buy pressure from other stocks and this one is already tanked some....at best, it give just slight gains, not enough to keep you all happy when you see these hurricane stocks go crazy and then tell yourslef you were dumb for not listening to me....good luck, this stock is good in the long though, but best to put your money where you can make some serious green...
disclaimer - only if ernesto keeps its cat 3/4 forcast and remains on course....
go NSMG, WEGI, BUGS, ECCI
-------------------- GSUS - Eternal 100 Bagger! HCPC - my favorite potential into December Posts: 525 | From: nashville | Registered: Jun 2005
| IP: Logged |
Advanced Cell Technology raises money after stem cell news East Bay Business Times - 1:55 PM PDT Friday Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed Just two days after reporting it had developed a new way to generate human embryonic stem cells, Advanced Cell Technology Inc. said it had commitments to raise about $13.5 million.
The Alameda company (OTCBB: ACTC) said most holders of debentures and warrants to buy its stock agreed to exercise their options to buy more. Advanced Cell Technology will raise about $8.5 million that way.
The company will also exercise some of its outstanding warrants to raise another $5 million.
Because of the new agreements, Advanced Cell Technology canceled a proposed private placement through which it had hoped to raise about $11.3 million.
The company said Wednesday that its scientists generated human embryonic stem cells without harming embryos.
EDITORIAL: Little enthusiasm for new stem-cell technique Aug 28 2006 8:04AM ET
ACTC -- Advanced Cell Technology, Inc. Com ($0.001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
EDITORIAL: Little enthusiasm for new stem-cell technique
Aug 28, 2006 (The Kansas City Star - McClatchy-Tribune Business News via COMTEX) -- A reported "breakthrough" development in stem-cell research has received an appropriately lackluster reception from many scientists. Advanced Cell Technology, a Massachusetts-based biotech lab, said it could develop stem-cell lines from a single cell that would be removed from an embryo at a very early stage of development.
The company's officers promoted their technique as a compromise in the controversy over using human embryos for medical research. The embryo would retain the potential for development, they said, while new stem-cell lines could be used in the search for cures.
But for most scientists, and most Americans, no compromise is necessary.
Embryonic stem-cell research involves either using embryos left over from fertility procedures, which would otherwise be discarded; or using an electronic or chemical catalyst to coax a human egg to develop in a lab dish.
Either procedure involves miniscule clusters of cells. Attempts to describe them as research on human beings are deceptive.
The technique proposed by Advanced Cell Technology is technically difficult, and its ability to generate stem-cell lines is unproven, according to William Neaves, president of the Stowers Institute for Medical Research in Kansas City.
It isn't an acceptable substitute for somatic cell nuclear transfer, the procedure some Missouri politicians wrongheadedly are trying to ban.
That procedure has the potential to create healing cells that are a genetic match with the patient. Also, scientists think that cells acquired through somatic cell nuclear transfer are vital for teaching researchers how to repair damaged nerves, limbs and organs.
Last week's announcement by Advanced Cell Technology does speak to the eagerness among scientists to advance stem-cell research.
A proposed constitutional amendment on the Nov. 7 ballot in Missouri would guarantee the state's universities and research institutions the right to conduct all scientific research not banned by federal law. As a bold attempt to safeguard ethical, potentially lifesaving science, it deserves enthusiastic support.
(c) 2006, The Kansas City Star, Mo.
SUBJECT CODE: KC
Search for Dun & Bradstreet reports on this company.
Posts: 4071 | Registered: Dec 2005
| IP: Logged |
SmallCap Sentinel: Breakthroughs Recharge Interest in Non-Controversial Stem Cell Equities IRVINE, Calif., Aug. 28, 2006 (PRIMEZONE) -- "Last week's headline-grabbing stem cell breakthrough by Advanced Cell Technology, Inc. (OTCBB:ACTC) sent the company's shares skyrocketing upward," stated SmallCap Sentinel analyst D.R. Clark. "But it also brought attention to a sub-group of non-controversial stem cell companies like Medistem Laboratories, Inc. (OTCBB:MDSM).
"Whether you agree with funding limitations or other restrictions on stem cell research, the reality is that for the most part, companies with research processes unencumbered by glaring ethical constraints may find themselves in vogue," Clark noted. "And if the kind of headlines we saw last week start coming from non-controversial companies such as Medistem Laboratories (OTCBB:MDSM), the political arguments might someday be moot."
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the company believes to be non-controversial sources of stem cells. The company's business strategy calls for the establishment of a series of adult stem cell banks and clinics around the world to deliver unprecedented, next-generation adult stem cell therapies.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 previously by Advanced Cell Technology, Inc. for preparation and distribution of reports and other advertising services. MP has been paid $1,500 by Medistem for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.